1. Adelaide Research & Scholarship

Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 31-40 of 45 (Search time: 0.004 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2009Abdominal adiposity and liver fat content 3 and 12 months after gastric banding surgeryHeath, M.; Kow, L.; Slavotinek, J.; Valentine, R.; Toouli, J.; Thompson, C.
2010A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database studyGordon, J.; Pockett, R.; Tetlow, A.; McEwan, P.; Home, P.
2013Smoking termination opportunity for in patients (STOP): Superiority of a course of varenicline tartrate plus counselling over counselling alone for smoking cessation: A 12-month randomised controlled trial for inpatientsSmith, B.; Carson, K.; Brinn, M.; Labiszewski, N.; Peters, M.; Fitridge, R.; Koblar, S.; Jannes, J.; Veale, A.; Goldsworthy, S.; Litt, J.; Edwards, D.; Esterman, A.
2010Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Hughes, T.; Hochhaus, A.; Branford, S.; Muller, M.; Kaeda, J.; Foroni, L.; Druker, B.; Guilhot, F.; Larson, R.; O'Brien, S.; Rudoltz, M.; Mone, M.; Wehrle, E.; Modur, V.; Goldman, J.; Radich, J.
2009Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutationsMuller, M.; Cortes, J.; Kim, D.; Druker, B.; Erben, P.; Pasquini, R.; Branford, S.; Hughes, T.; Radich, J.; Ploughman, L.; Mukhopadhyay, J.; Hochhaus, A.
2009Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A TrialApperley, J.; Cortes, J.; Kim, D.; Roy, L.; Roboz, G.; Rosti, G.; Bullorsky, E.; Abruzzese, E.; Hochhaus, A.; Heim, D.; De Souza, C.; Larson, R.; Lipton, J.; Khoury, J.; Kim, H.; Sillaber, C.; Hughes, T.; Erben, P.; Tornout, J.; Stone, R.
2011Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up resultsKantarjian, H.; Giles, F.; Bhalla, K.; Pinilla-Ibarz, J.; Larson, R.; Gattermann, N.; Ottmann, O.; Hochhaus, A.; Radich, J.; Saglio, G.; Hughes, T.; Martinelli, G.; Kim, D.; Shou, Y.; Gallagher, N.; Blakesley, R.; Baccarani, M.; Cortes, J.; le Coutre, P.
2011Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b studyKotasek, D.; Tebbutt, N.; Desai, J.; Welch, S.; Siu, L.; McCoy, S.; Sun, Y.; Johnson, J.; Adewoye, A.; Price, T.
2010Phase III, randomized, open-label study of daily Imatinib Mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine Kinase Inhibitor Optimization and Selectivity StudyCortes, A.; Baccarani, M.; Guilhot, F.; Druker, B.; Branford, S.; Kim, D.; Pane, F.; Pasquini, R.; Goldberg, S.; Kalaycio, M.; Moiraghi, B.; Rowe, J.; Tothova, E.; de Souza, C.; Rudoltz, M.; Yu, R.; Krahnke, T.; Kantarjian, H.; Radich, J.; Hughes, T.
2013The outcomes of patients with ESRD and ANCA-associated vasculitis in Australia and New ZealandTang, W.; Bose, B.; McDonald, S.; Hawley, C.; Badve, S.; Boudville, N.; Brown, F.; Clayton, P.; Campbell, S.; Peh, C.; Johnson, D.

Discover